Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials

BACKGROUND: Inflammation is a key driver of atherosclerotic cardiovascular disease. C-reactive protein (CRP), an established biomarker of inflammation, is commonly elevated in people with overweight/obesity. METHODS: STEP 1, 2, and 3 were 68-week, placebo-controlled trials of semaglutide for weight...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Subodh, Bhatta, Meena, Davies, Melanie, Deanfield, John E., Garvey, W. Timothy, Jensen, Camilla, Kandler, Kristian, Kushner, Robert F., Rubino, Domenica M., Kosiborod, Mikhail N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713290/
https://www.ncbi.nlm.nih.gov/pubmed/36467859
http://dx.doi.org/10.1016/j.eclinm.2022.101737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713290/
https://www.ncbi.nlm.nih.gov/pubmed/36467859
http://dx.doi.org/10.1016/j.eclinm.2022.101737

Ejemplares similares